Retraction statement: A double‐blind placebo‐controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease

Peyronie’s disease is a condition that causes abnormal healing of the tunica albuginea, causing penile curvature. It is difficult to treat and its management is continuing to evolve. Proposed non-surgical treatments have included oral, topical, intralesional, extracorporeal shockwave, and traction therapy. The study of Peyronie’s disease is made difficult by heterogeneity in the timing of presentation, severity and characteristics of deformity, and associated complaints. Moreover, meta-analyses of studies are difficult due to inconsistencies across study endpoints and the duration of treatments. This article reviews the current clinical evidence and guideline recommendations, with a focus on an improvement in penile curvature.

show abstract

“…The only randomized placebo-controlled trial of pentoxifylline has been retracted due to “statistical inconsistencies” [46].…”

Section: Oral Therapymentioning

confidence: 99%

Medical Management of Peyronie’s Disease: Review of the Clinical Evidence

Teloken

Katz

2019

Medical Sciences

View full text Add to dashboard Cite

show abstract

Contemporary Review of Peyronie’s Disease Treatment

Capoccia

Levine

2018

Curr Urol Rep

View full text Add to dashboard Cite

Intracavernosal injection therapy using collagenase clostridium histolyticum (CCH) has been widely adopted since its FDA approval in 2013. Based on the current evidence, it appears to be moderately efficacious for men with mild curvatures. Although a recent study has shown similar outcomes using a modified protocol requiring fewer injections, CCH remains an expensive medication. Surgery provides the most definitive treatment. The most common adverse effect following surgery is perceived loss of length. Length restoration procedures have recently been developed to address this with promising results reported in small series. There are a variety of medical treatment options for PD, with CCH getting the most attention for being the first drug to be FDA approved for PD treatment. It is the authors' opinion that the non-surgical therapy most likely to provide meaningful results is combination therapy utilizing oral, intralesional, and external traction therapy. Surgery remains the gold standard for definitive treatment.

show abstract